

Edgar Filing: AVENTIS - Form 425

AVENTIS
Form 425
January 28, 2004

Filed by Sanofi-Synthelabo
Pursuant to Rule 135 and Rule 425(a) under the
United States Securities Act of 1933, as amended,
and deemed filed pursuant to Rule 14d-2(b)(2) of the
United States Securities Exchange Act of 1934, as amended

Subject Company: Aventis
Commission File No. 001-10378
Date: January 28, 2004

ON JANUARY 28, 2004, THE FOLLOWING ADVERTISEMENT WAS PUBLISHED ON
BEHALF OF SANOFI-SYNTHELABO IN THE FINANCIAL TIMES EUROPEAN EDITION.

* * * *

WE REFUSE TO ACCEPT THAT THERE ISN'T
A FASTER WAY TO FIND A MEDICINE
FOR TOMMY'S DISEASE.

[Image of child in hospital bed]

Who is going to tell Tommy that the medicine that could cure him won't be ready
for 20 years? You? No.

No one. Joining forces with Aventis will represent a giant step forward for
research. We will be able to provide patients with new drugs and innovative
solutions faster. Together, we will harness our complementary skills to create a
leading pharmaceutical group (No.1 in Europe and No.3 worldwide) committed to
improving healthcare and capable of driving strong, sustainable and profitable
growth.

SANOFI-SYNTHELABO'S OFFER TO AVENTIS'S SHAREHOLDERS
BECAUSE HEALTH MATTERS

This advertisement does not constitute an offer to sell or an offer to purchase
any securities

www.sanofi-synthelabo.com